Background and Purpose: Angiotensin converting enzyme (ACE) inhibitors are expected to modulate neuronal activities. The present study was designed to examine the beneficial effects of ACE inhibitors on microcirculation and metabolism in the ischemic brain.
See Editorial Comment, page 1566 related to the sulfhydril moiety in its structure.
Karanewsky et a19 synthesized a new ACE inhibitor, SQ 29 ,852, with a phosphonic acid group that binds to zinc at the active center of ACE to overcome the problems of captopril. Barnes et al10 and Costal et al"l showed that both SQ 29,852 and captopril administered in rats increase the performances in tests of cognitive function and block the neuronal deficits induced by scopolamine. The ability of ACE inhibitors to modulate the neuronal activity and function is disputed and may involve the activation of metabolism of neuropeptides and the cholinergic system. 12"l3 Recent reports have demonstrated that ACE inhibitors attenuate the consequences of cerebral ischemia in renovascular hypertensive rats14 and improve neurological outcome from cerebral ischemia in normotensive rats. 15 In the present study, we investigate whether the above-mentioned two ACE inhibitors, SQ 29, 852 and captopril, beneficially attenuate the metabolic and circulatory derangement in the ischemic brain in spontaneously hypertensive rats (SHR).
Materials and Methods Previously, we reported that female SHR are more resistant to cerebral ischemia, and the survival rate is higher than in male SHR. 16 Therefore, we used female SHR in this study. Six-month-old SHR, weighing 255 to 280 g, were separated into four groups: (1) control rats (n=7) for the measurement of cerebral blood flow (CBF) and metabolites, (2) vehicle-treated rats (n=7) for the determination of CBF and metabolites after 60 minutes of cerebral ischemia, (3) rats (n=14) subjected to 60 minutes cerebral ischemia after administration of SQ 29,852 0.1 or 10 mg/kg IV, and (4) rats (n=14) with 60 minutes of cerebral ischemia after the treatment of captopril 0.1 or 10 mg/kg IV. The drugs were stored as dry powder at 5oC and protected from light. Just before the study, the drugs were dissolved in 0.9% saline, and a 1 mL/kg solution was made for injection in each rat. Vehicle-treated rats received 1 mL/kg saline.
The rats were anesthetized with amobarbital (100 mg/kg IP), and one femoral artery was cannulated for the continuous measurement of arterial pressure and sampling blood for blood gases. One femoral vein was cannulated for drug administration. A midline incision was made in the neck, and both common carotid arteries were carefully exposed and separated from the surrounding connective tissue and nerve fibers. Supratentorial ischemia for 60 minutes was produced by bilateral carotid artery occlusion with Heifetz clips. The animals breathed room air spontaneously, and the rectal temperature of each rat was maintained close to 37°C throughout the experiment by a heating pad. Arterial blood samples were taken at rest and at 60 minutes of ischemia. CBF Measurement CBF to the parietal cortex was measured with the H2 clearance method. The animal's head was fixed in a head holder and the skull bone exposed. A small burr hole was made in the skull 2 mm lateral to the bregma on one side. A Teflon-coated platinum electrode, 200 gm in diameter, with 1 mm at its top uncoated and plated with platinum black, was placed in the parietal cortex 1 mm in depth from the surface of the brain through use of a stereotaxic apparatus. The reference electrode was an Ag-AgCI electrode inserted under the skin in the neck. H2 clearance curves were obtained after the inhalation of 10% H2 gas with room air, and blood flow was calculated from the clearance curve using the formula of Aukland et al. '7 After allowing more than 30 minutes for the steady state to be reached, at least two baseline CBFs were measured at intervals of about 10 minutes.
The animals then received 0.1 or 10 mg/kg IV SQ 29,852, captopril, or saline. Arterial blood pressure reached stable levels 15 minutes after administration of the drugs, and new values for CBF were estimated. Cerebral vascular resistance (CVR), calculated by mean arterial pressure/CBF, was determined before and 15 minutes after administration of the drugs in each rat. Then both carotid arteries were occluded, and CBF was measured at 30 and 60 minutes of ischemia.
Cerebral Metabolism
At the end of the experiment, a plastic funnel was fitted into the skin by pouring liquid nitrogen over the area. The whole frozen brain was chiseled out carefully and separated grossly into the supratentorial and infratentorial portions. The parts of the brain were weighed rapidly and ground after the addition of cold perchloric acid, 1N. The tissue homogenates, kept at 0°to 4°C, were centrifuged and neutralized with 3N KOH at pH 5.6 +0.1. Lactate, pyruvate, and ATP concentrations in the homogenate were determined by a standard enzymatic method as described previously.18.19 Statistical Analysis All data were expressed as mean+SEM. The significance of differences in CBF, arterial pressure, and cerebral metabolites among the groups was examined by ANOVA followed by Scheff6's test. The changes in CBF and arterial pressure in each group were analyzed by repeated measurement of ANOVA.
Results
The resting values in Pao, and Paco2 were around 95 and 35 mm Hg, respectively, without differences between groups. Bilateral carotid artery occlusion caused hyperventilation in all animals, and Paco2 significantly decreased to 19 to 22 mm Hg and pH increased by 0.04 to 0.09 after 60 minutes of ischemia ( Fig 3) . After 60 minutes of ischemia, lactate levels in vehicle-treated rats increased 6.6-fold and ATP decreased to 65% of the control values. L/P ratio also increased 5.2 times the control. Administration of ACE inhibitors significantly reduced the rise in such lactate levels to 1.6-to 3.1-fold (P<0.05 vs vehicle-treated rats).
The supratentorial ATP was well preserved to 82% to 93% of the control level by administration of high doses of both SQ 29,852 and captopril (P<.05 vs vehicletreated rats, respectively). Similarly, the levels of pyruvate tended to be well preserved and thus, L/P ratio was significantly lowered to 4 On the other hand, vasoconstriction, if indeed exercised directly at any level of the cerebral circulation, may act to further compromise blood flow in addition to the systemic hypertensive effect.5 Interestingly, no clear evidence has been generated in support for a direct neurotoxic effect of angiotensin II on neurons. In view of the paucity of information about the role of angiotensin II in regulation of the cerebral circulation and in stroke, the case for ACE inhibitors in prevention and treatment of stroke is quite perplexing. First, there is no study on the effect of ACE inhibitors in reduction of stroke in hypertensive patients. However, it is commonly accepted that ACE inhibitors, by virtue of reducing the hypertensive state, may provide protection from strokes as do other antihypertensive modalities. However, some beneficial effects of ACE inhibitors may be related to their effect on cerebral autoregulation, resetting it at lower blood pressure thereby protecting the brain from sudden hypotensive events. 6 The downside of lowering the upper limit of autoregulation by ACE inhibitors could be harmful because it would reduce the protection against sudden hypertensive surges.
Recent preclinical work provided evidence in support of the capacity of ACE inhibitors to attenuate consequences of cerebral ischemia in renovascular hypertensive rats7 and improve neurological outcome from cerebral ischemia in normotensive rats.5 In the present study by Sadoshima et al (this volume) the authors report that two different ACE inhibitors, SQ 29,852 and captopril, administered 15 minutes before bilateral carotid artery occlusion in spontaneously hypertensive rats reduce lactate accumulation and preserved brain ATP levels 60 minutes after brain ischemia. The mechanism of the ACE inhibitors' effects on brain energy and anerbic metabolism are not clear.
Monitoring cerebral blood flow (H2-clearance, microcirculation) revealed no consistent differences between treated and nontreated animals, suggesting that microhemodynamic factors did not play an important role in the anti-ischemic effect of the ACE inhibitors. Furthermore, the beneficial effects of the low doses of SQ 29,852 and captopril on the energy and metabolic states of the ischemic brain while having no hemodynamic effects further support a nonvascular/circulatory mechanism.
If ACE inhibitors act to protect the brain from ischemic injury via a nonvascular/hemodynamic mechanism, several possibilities must be considered: (1) Angiotensin II may be toxic to the ischemic brain and therefore inhibition if its synthesis results in neuroprotection. (2) A substrate for ACE accumulates in the brain after ACE inhibition. Such a metabolite may include bradykinin, but other kinins or peptides (not yet identified) cannot be ruled out. (3) Finally, other pharmacological properties of the drugs, eg, antioxidants, or a peripheral site of action should not be ignored.
In summary, this study, along with a few previous reports, should encourage investigators to explore further the mechanism of the prophylactic and therapeutic potential of ACE inhibitors, a class of more than 15 members approved for clinical use in various therapeutic indication (eg, hypertension, congestive heart failure). In fact, a full-scale study for primary and second-
